HDA UK Media And Political Bulletin – 3 November 2017

Media and Political Bulletin

3 November 2017

Media Summary

The pharmaceutical industry view on the Government’s response to the Accelerated Access Review

ABPI, 3 November 2017

The ABPI comments on the Government’s response to the Accelerated Access Review (AAR) published today. The Accelerated Access Review was launched in a bid to dramatically speed up the time it takes for patients to benefit from ground-breaking treatments for conditions such as cancer, dementia and diabetes.

The Government’s announcement today follows last year’s final report from the indep​endently-chaired AAR. The overall aim of the Review was to make the UK “the fastest place in the world for the design, development and widespread adoption of medical innovations and stimulate new investment, jobs and economic growth to support the NHS.”

In its response, the Government announced Sir Andrew Witty, former Chief Executive of GlaxoSmithKline will lead the Accelerated Access Collaborative, which will make decisions on which products should be granted access to the Accelerated Access Pathway.

Patients to get breakthrough drugs on NHS

The Times, Chris Smyth, 3 November 2017

The Times reports on the creation of the new Accelerated Access Collaborative through which patients have been promised access to “breakthrough” drugs up to four years earlier than at present under plans to fast-track the most promising treatments.

The article highlights that charities have welcomed the plans, but questioned why it had taken ministers a year to accept the recommendations of a review into speeding up access to medicines.

Parliamentary Coverage

There is no Parliamentary coverage today.

Full Coverage

The pharmaceutical industry view on the Government’s response to the Accelerated Access Review

ABPI, 3 November 2017

The Government’s response to the Accelerated Access Review (AAR) was published today in a bid to dramatically speed up the time it takes for patients to benefit from ground-breaking treatments for conditions such as cancer, dementia and diabetes.

​The Government’s announcement follows last year’s final report from the indep​endently-chaired AAR, the aim of the Review was to make the UK “the fastest place in the world for the design, development and widespread adoption of medical innovations and stimulate new investment, jobs and economic growth to support the NHS.”

In it’s response, the Government announced Sir Andrew Witty, former Chief Executive of GlaxoSmithKline will lead the Accelerated Access Collaborative, which will make decisions on which products should be granted access to the Accelerated Access Pathway.

Commenting on the news, Dr Richard Torbett, Executive Director of Commercial Policy at The ABPI said:

“The Government’s commitment to speeding up access to the most innovative medicines and treatments is very much welcome.

This should benefit thousands of NHS patients as well as delivering significant long-term savings for the health service if appropriate investment in these transformative therapies is made available.

Over the next decade, breakthrough personalised therapies have the potential to transform treatment for many diseases, from cancers to diabetes to dementia. It is incumbent on everyone to tear down the barriers which have prevented access to medical progress of this kind.

Sir Andrew Witty’s extensive pharmaceutical industry leadership and experience will be vital in helping to deliver a system which prioritises patient access to transformative treatments. We are confident that the promise of making ground-breaking, cost-effective healthcare available for everyone, as quickly as possible, can be delivered through partnership with our industry, Government and the NHS.”

 

Patients to get breakthrough drugs on NHS

The Times, Chris Smyth, 3 November 2017

Patients have been promised access to “breakthrough” drugs up to four years earlier than at present under plans to fast-track the most promising treatments.

Experts will start identifying treatments that could make the biggest difference to patients while they are still in development, in order to push them through regulatory and NHS approval.

Charities welcomed the plans, but questioned why it had taken ministers a year to accept the recommendations of a review into speeding up access to medicines.

Sir Andrew Witty, the former head of Glaxosmithkline, will lead the Accelerated Access Collaborative. Richard Torbett, of the Association of the British Pharmaceutical Industry, said: “Over the next decade, breakthrough personalised therapies have the potential to transform treatment for diseases from cancers to diabetes to dementia.”

The drug companies will be expected to negotiate more flexible pricing deals with the NHS.

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?